Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder

Inclusion Criteria: Main prescription data analysis: \- At least one prescription for lisdexamfetamine dimesylate recorded in the NostraData database in Australia. For all sensitivity analyses (sensitivity analysis I, II and III): \- At least one prescription for lisdexamfetamine dimesylate recorded in the NostraData database in Australia during the defined observation period of the study. Physician survey: \- The physician prescribed lisdexamfetamine dimesylate for indications other than ADHD in the last 12 months for at least one participant. Participant population: \- Physician entered data for the participant until at least question 3 (treatment information (Q03); main indication). Exclusion Criteria: For all sensitivity analyses (sensitivity analysis I, II and III): * Evidence of use for lisdexamfetamine dimesylate for treatment of ADHD, as shown by prescription records for ADHD medication other than lisdexamfetamine dimesylate at any time. * Record of at least one lisdexamfetamine dimesylate prescription prior to launch of lisdexamfetamine dimesylate for BED (02/17/2018). Additional exclusion criteria for the specific sensitivity analyses: For sensitivity analysis I: \- Prescriptions for lisdexamfetamine dimesylate issued by pediatricians or child psychiatrists. For sensitivity analysis II: \- Prescriptions for lisdexamfetamine dimesylate issued by all prescribers other than psychiatrists (example, pediatricians, general practitioner \[GPs\]). For sensitivity analysis III: * Prescriptions for lisdexamfetamine dimesylate issued by pediatricians or child psychiatrists. * For participants with age available, participants with evidence for age at first prescription below 18 years. Physician survey and participant population: \- Physician entered ADHD as main indication for prescription of lisdexamfetamine dimesylate (treatment information \[Q03\]) for the participant.